Clinical Trial

RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

Name: RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma — clinical trial record (NCT07445022)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.

Trial Details

NCT Number	NCT07445022
Lead Sponsor	Fudan University
Conditions	Melanoma Advanced
Enrollment	110 participants
Start Date	2026-01-28
Primary Completion	2028-09-30 (estimated)
Study Completion	2029-01-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-03